Exploring the Use of Lebrikizumab (Ebglyss, Eli Lilly and Company) in AD Patients With Darker Skin Tones Featuring Dr. Andrew Alexis
Lebrikizumab (Ebglyss, Eli Lilly and Company) improves signs and symptoms of atopic dermatitis (AD) in patients with darker skin tones, according to research presented at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, TN.